Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Hiran Orgochem Ltd (506170)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506170 NSE: Pharmaceuticals & Drugs | Small Cap | Hiran Orgochem Share Price
BSE Share Price
Not Listed
Not Listed
Hiran Orgochem Ltd (506170)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506170 NSE: Pharmaceuticals & Drugs | Small Cap | Hiran Orgochem Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹5 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
55
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-88.1%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
23.88%
Pledged shares (%) of Promoter's holding (%)
89.78%
Reserves
-
Equity
₹98.7 Cr.
Face Value
₹10
All Time Low / High
₹0.38 / 45.81
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Jun'11 | Jun'12 | Jun'13 | Mar'14 | Mar'15 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 41.4% | 7.4% | 9.1% | -11.4% | 15.4% | -50.2% | -5.6% | -65.6% | -12.5% | -102.4% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 115 | 108 | 119 | 189 | 203 | 118 | 38.9 | 24 | 3.5 | 0.4 | 0 |
| Sales YoY Gr. | - | -5.9% | 9.9% | 58.4% | 7.6% | -41.7% | -67.1% | -38.4% | -85.3% | -88.1% | - |
| Adj EPS ⓘ | 3.5 | 0.2 | 0.6 | -2.3 | 0.6 | -6.7 | -1.3 | -6.1 | -1 | -1 | 0.1 |
| YoY Gr. | - | -94.6% | 200% | -500% | NA | -1268.4% | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 12.2 | 16 | 16.6 | 13.6 | 14.9 | 3.4 | 3.3 | -2.8 | -4.7 | -6.3 | -3.5 |
| Adj Net Profit ⓘ | 13.5 | 1 | 3 | -12 | 3 | -65.7 | -13 | -59.7 | -9.6 | -10.2 | 1 |
| Cash Flow from Ops. ⓘ | -17.6 | -41 | 4.6 | 20.8 | 11.9 | -45.3 | 3.8 | -28.6 | -1.2 | -16.1 | - |
| Debt/CF from Ops. ⓘ | -1.9 | -1.2 | 12.4 | 2.5 | 4.5 | -1.7 | 23.2 | -3.1 | -92.5 | -4.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -46.4% | -71% | -77.9% | -88.1% | ||||
| Adj EPS ⓘ | -187.3% | -212.6% | NA | NA | ||||
| BVPSⓘ | -193% | -184.2% | -224.4% | NA | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Jun'11 | Jun'12 | Jun'13 | Mar'14 | Mar'15 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 43.2 | 1.5 | 3.5 | -15.1 | 3.9 | -136.1 | -35 | -2278.6 | 23.3 | 21 | -1.8 |
| Op. Profit Mgn % ⓘ | 21.1 | 7.2 | 9.8 | -3.7 | 6.3 | -45.5 | -31.4 | -244 | -243.2 | -829.9 | NAN |
| Net Profit Mgn % ⓘ | 11.7 | 0.9 | 2.5 | -6.4 | 1.5 | -55.5 | -33.4 | -249 | -272.7 | -2416.2 | INF |
| Debt to Equity ⓘ | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 2.3 | 2.8 | -3.2 | -2.5 | -1.1 | - |
| Working Cap Days ⓘ | 175 | 354 | 424 | 266 | 262 | 346 | 884 | 906 | 5,426 | 24,780 | 0 |
| Cash Conv. Cycle ⓘ | 48 | 120 | 112 | 47 | 23 | 72 | -23 | -110 | -782 | -6,807 | 0 |
Valuation of Hiran Orgochem - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 66.33 | 88.83 | 88.83 | 88.84 | 90.61 | 90.21 | 89.78 | 89.78 | 89.78 | 89.78 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Hiran Orgochem Ltd FAQs
The current trading price of Hiran Orgochem on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Hiran Orgochem stood at ₹4.74 Cr
The latest P/E ratio of Hiran Orgochem as of 31-Dec-1969 is 5.56.
The latest P/B ratio of Hiran Orgochem as of 31-Dec-1969 is -0.14.
The 52-week high of Hiran Orgochem is ₹0.48 and the 52-week low is ₹0.44.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Hiran Orgochem is ₹0.00 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Hiran Orgochem Ltd
Mumbai based Hiran Orgochem was Incorporated in 1983 is a leading integrated manufacturer of active pharmaceutical ingredients and formulations. Since its incorporation, Hiran has focused on Manufacturing the Quinolones group of API's with its principal products comprising Ciprofloxacin, Ofloxacin, Levofloxacin, Enrofloxacin and now provides formulations as well.
Hiran today is the largest Ciprofloxacin, Ofloxacin, Levofloxacin and Enrofloxacin manufacturer in India and strives to attain Global Leadership. The Company has achieved this position due to its strong commitment and ability to deliver unparalleled excellence in customer service. Hiran's Ability to provide services on a Quick-turn and cost-effective basis has resulted in successfully expanding its customer base and delivering solid operating returns.
The company is having presence in more than 56 Countries. Their Export percentage is about 40% - 45% of the total Sales Turnover. Currently we are working on approvals for US FDA, COS and TGA.
Product range of the company includes:
API
- Ciprofloxacin HCL / Base
- Ciprofloxacin Lactate
- Ciprofloxacin HCL Compacted
- Ciprofloxacin HCL Micronised
- Ofloxacin HCL / Base
- Levofloxacin Hemihydrate
- Quinine Sulphate
- Quinine BiSulphate
- Quinine HCL
- Quinine DiHCL
Veterinary Products
- Enrofloxacin Base / HCL / Lactate
- Difloxacin Base / HCL / Lactate
- Sarafloxacin Base / HCL / Lactate
Products under development
- Azithromycin
- Clarithromycin
- Omeprazole
- Pantoprazole Sodium
- Levocetirizine
- Danofloxacin Mesylate
- Fluconazole
- Losartan Potassium
- Atorvastatin
- Simvastatin
- Sildenafil Citrate
- Moxifloxacin
- Gemifloxacin
- Lomefloxacin
- Gatifloxacin
- Pefloxacin
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
